A study of Siplizumab for autoimmune liver disease patients awaiting transplant
Treatments studied
Part of Digestive system, Immune system & allergy clinical trials.
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a diagnosis of autoimmune hepatitis (AIH) or primary sclerosing cholangitis (PSC)
- You are currently listed for a liver transplant
- You have had Epstein-Barr virus (EBV) in the past, confirmed by a blood test within the last year
- You do not have other serious liver diseases like viral hepatitis or alcohol-related liver disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
This trial is testing a new way to see how well patients do after a liver transplant. It includes people with severe cirrhosis, other end-stage liver diseases, or liver cancer.
This trial tests whether fenofibrate can prevent primary sclerosing cholangitis (PSC) from coming back after a liver transplant. It is for adults who had a liver transplant for PSC between 1 and 7 years ago and have certain risk factors.
This Phase 2 study tests whether transplanting donor liver cells near lymph nodes can improve outcomes in people with advanced cirrhosis from certain liver conditions. It may help your liver function by adding healthy liver cells, but eligibility is tightly based on your current liver status and other health factors.
This trial tests a new medication called inebilizumab for people with autoimmune hepatitis (a condition where the body's immune system attacks the liver) who haven't responded well to standard treatments or can't tolerate them. The study aims to see if this new drug can help control liver inflammation and reduce the need for high-dose steroids.
This trial tests a new drug, siplizumab, to see if it helps the body accept a donated kidney better than a standard treatment. It is for people receiving a kidney transplant from a living or deceased donor.
Hear when a new Autoimmune Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.